196 related articles for article (PubMed ID: 35549626)
1. Exploring the rationale for red cell transfusion in myelodysplastic syndrome patients: emerging data and future insights.
Finelli C; Parisi S; Paolini S
Expert Rev Hematol; 2022 May; 15(5):411-421. PubMed ID: 35549626
[TBL] [Abstract][Full Text] [Related]
2. Hematologic improvement with iron chelation therapy in myelodysplastic syndromes: Clinical data, potential mechanisms, and outstanding questions.
Leitch HA; Gattermann N
Crit Rev Oncol Hematol; 2019 Sep; 141():54-72. PubMed ID: 31228649
[TBL] [Abstract][Full Text] [Related]
3. Red blood cell transfusion therapy and iron chelation in patients with myelodysplastic syndromes.
Malcovati L
Clin Lymphoma Myeloma; 2009; 9 Suppl 3():S305-11. PubMed ID: 19778858
[TBL] [Abstract][Full Text] [Related]
4. [Transfusions in myelodysplastic syndromes].
Rose C
Transfus Clin Biol; 2017 Sep; 24(3):209-215. PubMed ID: 28651884
[TBL] [Abstract][Full Text] [Related]
5. Iron overload in lower international prognostic scoring system risk patients with myelodysplastic syndrome receiving red blood cell transfusions: Relation to infections and possible benefit of iron chelation therapy.
Wong CAC; Wong SAY; Leitch HA
Leuk Res; 2018 Apr; 67():75-81. PubMed ID: 29477023
[TBL] [Abstract][Full Text] [Related]
6. Red blood cell transfusions and iron overload in the treatment of patients with myelodysplastic syndromes.
Jabbour E; Kantarjian HM; Koller C; Taher A
Cancer; 2008 Mar; 112(5):1089-95. PubMed ID: 18186499
[TBL] [Abstract][Full Text] [Related]
7. Supportive care and chelation therapy in MDS: are we saving lives or just lowering iron?
Leitch HA; Vickars LM
Hematology Am Soc Hematol Educ Program; 2009; ():664-72. PubMed ID: 20008252
[TBL] [Abstract][Full Text] [Related]
8. The clinical, quality of life, and economic consequences of chronic anemia and transfusion support in patients with myelodysplastic syndromes.
Platzbecker U; Hofbauer LC; Ehninger G; Hölig K
Leuk Res; 2012 May; 36(5):525-36. PubMed ID: 22300879
[TBL] [Abstract][Full Text] [Related]
9. Improvement of iron-mediated oxidative DNA damage in patients with transfusion-dependent myelodysplastic syndrome by treatment with deferasirox.
Kikuchi S; Kobune M; Iyama S; Sato T; Murase K; Kawano Y; Takada K; Ono K; Kaneko Y; Miyanishi K; Sato Y; Hayashi T; Takimoto R; Kato J
Free Radic Biol Med; 2012 Aug; 53(4):643-8. PubMed ID: 22705364
[TBL] [Abstract][Full Text] [Related]
10. Iron status and treatment modalities in transfusion-dependent patients with myelodysplastic syndromes.
Delforge M; Selleslag D; Triffet A; Mineur P; Bries G; Graux C; Trullemans F; MacDonald K; Abraham I; Pluymers W; Ravoet C
Ann Hematol; 2011 Jun; 90(6):655-66. PubMed ID: 21318574
[TBL] [Abstract][Full Text] [Related]
11. Overview of guidelines on iron chelation therapy in patients with myelodysplastic syndromes and transfusional iron overload.
Gattermann N
Int J Hematol; 2008 Jul; 88(1):24-29. PubMed ID: 18581200
[TBL] [Abstract][Full Text] [Related]
12. Iron overload in myelodysplastic syndromes (MDS) - diagnosis, management, and response criteria: a proposal of the Austrian MDS platform.
Valent P; Krieger O; Stauder R; Wimazal F; Nösslinger T; Sperr WR; Sill H; Bettelheim P; Pfeilstöcker M
Eur J Clin Invest; 2008 Mar; 38(3):143-9. PubMed ID: 18218040
[TBL] [Abstract][Full Text] [Related]
13. Iron overload in myelodysplastic syndromes: diagnosis and management.
List AF
Cancer Control; 2010 Jan; 17 Suppl():2-8. PubMed ID: 20125080
[TBL] [Abstract][Full Text] [Related]
14. Red Blood Cell Transfusion Dependency and Hyperferritinemia Are Associated with Impaired Survival in Patients Diagnosed with Myelodysplastic Syndromes: Results from the First Polish MDS-PALG Registry.
Waszczuk-Gajda A; Mądry K; Machowicz R; Drozd-Sokołowska J; Stella-Hołowiecka B; Mital A; Obara A; Szmigielska-Kapłon A; Sikorska A; Subocz E; Jędrzejczak WW; Dwilewicz-Trojaczek J
Adv Clin Exp Med; 2016; 25(4):633-41. PubMed ID: 27629836
[TBL] [Abstract][Full Text] [Related]
15. Optimizing therapy for iron overload in the myelodysplastic syndromes: recent developments.
Leitch HA
Drugs; 2011 Jan; 71(2):155-77. PubMed ID: 21275444
[TBL] [Abstract][Full Text] [Related]
16. Decision points in the treatment of transfusional iron overload in patients with myelodysplastic syndromes: why, when, and how to chelate.
Imran F; Phatak P
Expert Rev Hematol; 2017 Jan; 10(1):53-64. PubMed ID: 27923273
[TBL] [Abstract][Full Text] [Related]
17. Myelodysplastic syndromes: iron overload consequences and current chelating therapies.
Greenberg PL
J Natl Compr Canc Netw; 2006 Jan; 4(1):91-6. PubMed ID: 16403408
[TBL] [Abstract][Full Text] [Related]
18. Ironing out the details of iron overload in myelofibrosis: Lessons from myelodysplastic syndromes.
Carreau N; Tremblay D; Savona M; Kremyanskaya M; Mascarenhas J
Blood Rev; 2016 Sep; 30(5):349-56. PubMed ID: 27106071
[TBL] [Abstract][Full Text] [Related]
19. Overall survival in lower IPSS risk MDS by receipt of iron chelation therapy, adjusting for patient-related factors and measuring from time of first red blood cell transfusion dependence: an MDS-CAN analysis.
Leitch HA; Parmar A; Wells RA; Chodirker L; Zhu N; Nevill TJ; Yee KWL; Leber B; Keating MM; Sabloff M; St Hilaire E; Kumar R; Delage R; Geddes M; Storring JM; Kew A; Shamy A; Elemary M; Lenis M; Mamedov A; Ivo J; Francis J; Zhang L; Buckstein R
Br J Haematol; 2017 Oct; 179(1):83-97. PubMed ID: 28677895
[TBL] [Abstract][Full Text] [Related]
20. Red blood cell transfusion in myelodysplastic syndromes: A systematic review.
Kaka S; Jahangirnia A; Beauregard N; Davis A; Tinmouth A; Chin-Yee N
Transfus Med; 2022 Feb; 32(1):3-23. PubMed ID: 34927286
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]